Two-Drug combo aims to clear lingering cancer from blood
NCT ID NCT07264673
Summary
This study is testing whether adding a second drug called OSE2101 to standard maintenance therapy can better clear tiny traces of cancer from the blood of advanced lung cancer patients. It involves 160 patients who have a specific genetic marker and have already completed initial chemotherapy-immunotherapy treatment. The main goal is to see if the combination therapy leads to more patients having no detectable cancer DNA in their blood compared to standard care alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Istituti Fisioterapici Ospitalieri- Ifo - Istituto Regina Elena
RECRUITINGRoma, RM, 00144, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.